Nuvation Bio Inc. (NUVB) - Stock Analysis
Last updated: Mar 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Nuvation Bio’s strong commercial execution of IBTROZI with $55 million annualized revenue run rate, progression in clinical trials, positive analyst upgrades, and steady technical upward momentum suggest a compelling near-term growth opportunity supported by robust liquidity and constructive sector backdrop.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong liquidity • Large operating losses • Negative cash flow NUVB has strong liquidity and gross margins but is burning cash with large operating losses, negative returns and cash flow, while trading at rich multiples.
Price Behavior
Key Price Behavior Insights: • Downward momentum • Large gap-down • Defined support/resistance Support Level: $4.36–$4.59 Resistance Level: $5.70–$5.90 Over the last month NUVB has turned clearly short-term bearish—down ~18% to $4.59 with a disruptive gap to $4.36 that raises downside risk while support sits at $4.36–$4.59 and resistance near $5.70–$5.90.
Sentiment & News
Key News Insights: • IBTROZI uptake • Safusidenib Phase 3 • Legal investigations Nuvation Bio shows strong commercial and clinical momentum—IBTROZI uptake, safusidenib advancing to Phase 3 and an Eisai deal with analyst support—offset by two securities/governance investigations.
AI Summary
NUVB has shifted from a binary clinical story to a nascent commercial oncology company where IBTROZI revenue trajectory and a ~$529M cash runway now drive valuation, so investors should demand clear evidence of accelerating patient starts, durable payer coverage, and improving gross‑to‑net to convert strong product gross margins into positive cash flow. If sequential revenue and FCF improvement do not materialize, expect dilution or cost cuts—require either sustained revenue acceleration or clear non‑dilutive partnership milestones (e.g., Eisai triggers) before treating the recent gap‑down as a buy.
Description
Nuvation Bio is a clinical-stage biopharmaceutical company developing small-molecule therapies for oncology, with its lead candidate NUV-422 targeting CDK2, CDK4 and CDK6. Its pipeline also includes oral inhibitors affecting BET proteins, Wee1 kinase, and adenosine receptors, along with a drug–drug conjugate platform that pairs PARP inhibition with cytotoxic warheads to treat cancers including ER+ breast and ovarian tumors. The company was founded in 2018, rebranded from RePharmation in 2019, and is based in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 5 | Jan 12 | NUVB | Nuvation Bio Inc. | Nuvation Bio’s strong commercial execution of IBTROZI with $55 million annualized revenue run rate, progression in clinical trials, positive analyst upgrades, and steady technical upward momentum suggest a compelling near-term growth opportunity supported by robust liquidity and constructive sector backdrop. | Closed | -24.8% |
| Sep 15 | Sep 22 | NUVB | Nuvation Bio Inc. | Nuvation Bio’s near-term FDA approval and early commercial launch of IBTROZI™, strong cash runway, and positive technical signals with a 13.8% gain over three weeks establish it as a hot idea, balanced with caution on volatility and rising leverage risks before more commercial data emerge. | Closed | +3.8% |